The Decision Room:

The Anatomy of a Rare Disease Treatment Decision

The clinical and social forces that shape treatment choices. 

March 26, 2026

1:00 PM ET

60-minute webinar

You’ll benefit most if you are:

Pharma Brand and Agency Leaders focused on authentic patient engagement and brand trust for Rare Disease Patients.

Event Summary

Join Bionews for a 60-minute roundtable designed for pharma brand leaders and agency strategists who want a clearer view of how rare disease treatment decisions truly take shape.

This session brings rare disease patients and healthcare providers into the same conversation to examine the full decision arc, from pre-visit preference formation to the clinical encounter to the reflection period that follows. Together, they will unpack how treatment narratives form before the appointment, how risk, time pressure, and power dynamics shape what happens in the room, and where decisions ultimately solidify or stall afterward. Expect candid discussion about misalignment, information influence, trust signals, and the systemic constraints that shape real-world care.

If your work depends on influencing treatment conversations, this session will help you understand where those conversations are actually won, lost, or reframed.

Panelists

Kerry L. Wong

Sarcoidosis Patient

Mai ElMallah, MD MS

Pediatric Pulmonologist

Tanita Allen

Huntington’s Disease Patient

Danita LaShelle Jones

Caregiver for Hereditary Angioedema

Ethan Ash

Chief Commercial Officer, Bionews

Dr. Natalie Katz

Assistant Professor of Pediatrics (Neurology)

Key Discussion Topics

The Pre-Clinical Build

How treatment preferences begin forming before the appointment. Prior experiences, peer narratives, digital information, emotional readiness, and expectations about the physician. What is already “decided” before the conversation starts.

Decision Dynamics in the Room

How time limits, language, perceived authority, and framing effects shape the discussion. Where clarity increases and where ambiguity creeps in. What is emphasized versus what quietly drops out.

The Commitment Threshold

When a treatment choice becomes real. Prescription, insurance approval, first dose, family discussion, or community validation. Where momentum accelerates and where decisions stall.

Structural Misalignment and Leverage Points

Where patient and provider expectations diverge most sharply, and where systemic constraints interfere. What can realistically be improved and what is embedded in the system.

Four components. One decision. Treated as a process under pressure, not a slogan.

Ideal For

Pharma Brand

Agency Account Leads & Planners

Why Attend

A structured view of pre-visit decision architecture and how preferences begin forming before clinicians enter the conversation

Insight into real-time dynamics inside the exam room, including risk framing, time compression, and trust signals

A clearer understanding of where decisions solidify, stall, or unravel after the appointment

A grounded discussion of misalignment between patients and providers and where meaningful intervention may or may not be possible

Key Takeaway

Attend to see where treatment decisions actually solidify, unravel, or quietly shift so you can align your strategy to the real inflection points instead of the assumed ones.

March 26, 2026

1:00 PM ET

60-minute webinar + Q&A